DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for early-onset Lafora body disease — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEarly-onset Lafora body disease maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for early-onset lafora body disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2008 case report describes a patient with first visual symptoms at age 19, a generalised tonic-clonic seizure at 20, and myoclonus appearing weeks later. Massive cognitive dysfunction was apparent three months after the first seizure, and mental deterioration continued even though seizures were controlled by medication and myoclonus remained minimal. The diagnosis was confirmed by axillary skin and muscle biopsies showing Lafora bodies. The authors state that the clinical presentation alone can be sufficient for diagnosis even in atypical cases.
A 2016 report describes an 11-year-old boy who first presented with aggressive behaviour, abnormal movements, and declining intellectual function, and was initially treated for attention deficit hyperactivity disorder. Axillary skin biopsy led to the diagnosis of Lafora body disease. The child was discharged on symptomatic treatment only, and the authors note that Lafora body disease should be considered in children with neuropsychiatric symptoms.
A 1993 case history confirms that the EEG in Lafora body disease is consistently abnormal and deteriorates as the patient’s clinical condition worsens. The diagnosis was again confirmed by skin biopsy showing Lafora bodies. Across all three reports, no disease-modifying therapy is described; management is limited to seizure control and symptomatic care. No drug is mentioned in any of the abstracts as a treatment for the underlying disease.
What is still missing is any clinical trial of a drug intended to slow or halt disease progression, any validated biomarker for early diagnosis before cognitive decline is established, and any systematic effort to stratify patients by genetic mutation or age of onset for future therapeutic studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
European Neurology · 2008 · 15 citations
Semi-Late Onset and Rapidly Progressive Case of Lafora’s Disease with Predominant Cognitive Symptoms
AbstractThe authors report a sporadic case of Lafora's disease, unusual for the comparatively late age at onset and atypical evolution. Discrete visual phenomena that may be considered as partial seizures occurred at age 19 years. A generalized tonic-clonic seizure occurred at 20 years of age and myoclonus became apparent a few weeks later. A massive cognitive dysfunction was clearly apparent 3 months after the first seizure and further mental deterioration occurred although seizures were controlled by medication and myoclonus remained minimal. The EEG showed the typical association of generalized and focal (occipital) changes. Axillary++ skin and muscle biopsies were positive and easily confirmed the diagnosis. The clinical presentation of Lafora's disease is considered by the authors to be sufficient for a clinical diagnosis, even in such an atypical case. Confirmation by skin biopsy is easily obtainable.
Pediatric Review International Journal of Pediatric Research · 2016 · 1 citations · open access
Lafora body disease presenting as neuropsychiatric illness
AbstractBackground: Lafora disease is a rare progressive myoclonus epilepsy with an autosomal recessive inheritance characterized by seizures, myoclonus and progressive cognitive decline. Case characteristics: An 11 year old boy presented with complaints of aggressive behavior, abnormal movements and declining intellectual function and was earlier treated as a case of attention deficit hyperactivity disorder. The child was subjected to Axillary skin biopsy as a part of evaluation and diagnosed as a case of Lafora body disease. parental counselling done and the child was discharged on symptomatic treatment. Message: Lafora body disease should be kept in mind while evaluating a child with neuropsychiatric manifestations.
American Journal of EEG Technology · 1993 · 0 citations
Progression of the EEG in Lafora-Body Disease
Abstract.Lafora-body disease is classified as progressive myoclonus epilepsy. The disease is characterized by the triad of epilepsy, myoclonus, and progressive dementia. Deposits called Lafora bodies are found in the central nervous system and other organs, including the liver and skin. In this case history, the diagnosis of Lafora-body disease was confirmed by the finding of Lafora bodies in a skin biopsy. The EEG in Lafora's disease has consistently been reported as abnormal. As the patient deteriorates clinically, the EEG also deteriorates, as shown in our case study.
Lafora disease: a report of five cases diagnosed by skin biopsy
AbstractObjective To investigate the clinical manifestions, pathological features and diagnosing methods of Lafora disease. Methods The chnical and pathological features of 5 patients with Lafora disease who were diagnosed by axillary biopsies were systemically studied. The specimen were stained by HE, PAS and AB-PAS methods. Results Four of 5 cases had an onset during adolescence and 1 during adulthood. All cases presented with progressive generalized tonic-clonic seizure, myoclonus and dementia. Emotional disturbance, dysarthria and ataxia appeared in the early course of the disease. Lafora bodys were identified in myoepithelial cells and duct cells of both eccrine sweat glands and apecrine sweat glands in the biopsies of axillary skin. Conclusions Lafora disease could be confirmed by round and oval periodic acid-Schiff- positive inclusions in skin biopsy specimen combined with the proper clinical settings. Both axillary and other skins can be chosen as the sites of biopsy.
Key words:
Lafora disease; Biopsy
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
